Ben Franklin client Cernostics, a pioneer in delivering spatialomics to the clinic, announced that new results from clinical studies on its TissueCypher® Barrett’s Esophagus Assay will be presented at Digestive Disease Week® (DDW®) 2021, taking place May 21-23. Clinical studies by Mayo Clinic, and Academic Medical Center in The Netherlands, two of the world’s leading academic institutions in the area of diagnosis and treatment of Barrett’s esophagus (BE) and esophageal cancer prevention, will be presented during the oral lecture session focused on predicting progression to esophageal cancer in patients with BE.

“New data accepted for presentation at this year’s DDW® point to the value of TissueCypher® for improving prevention of esophageal cancer, particularly to help physicians and patients make more informed management decisions based on the unique biology of individual patients’ esophageal biopsies,” said Mike Hoerres, Cernostics’ chief executive officer. “We believe such data demonstrate the value of precision medicine testing with the TissueCypher® Barrett’s Esophagus Assay, and greatly appreciate the Barrett’s esophagus clinical experts who led and participated in these studies.” Read more.